Skip to main
RXST

RxSight (RXST) Stock Forecast & Price Target

RxSight (RXST) Analyst Ratings

Based on 9 analyst ratings
Hold
Strong Buy 11%
Buy 0%
Hold 67%
Sell 22%
Strong Sell 0%

Bulls say

RxSight Inc. has demonstrated robust revenue growth, with its recent performance exceeding consensus estimates, prompting management to raise the mid-point of its guidance for 2025. The company anticipates sustaining double-digit growth fueled by increased utilization of its light adjustable lens (LAL) technology and a growing installed base. Furthermore, RxSight has improved its gross margin expectations for 2025, which reflects a positive trajectory in financial health and operational efficiency.

Bears say

The financial performance of RxSight Inc. is concerning, with a reported revenue decline of 14% year-over-year, exacerbated by a significant drop in the monthly utilization of light adjustable lenses (LALs), which fell from 10.1 in 3Q24 to 8.0 in 3Q25. The company has also seen a drastic reduction in the placement of delivery devices (LDDs), with only 25 placed in 2Q25, marking a 68% year-over-year decrease and a 38% decline quarter-over-quarter. Further compounding these issues are risks related to limited market adoption of its product, challenges in commercial execution, intensified competition, and the potential need for dilutive financing, all of which contribute to a negative outlook for the company's stock.

RxSight (RXST) has been analyzed by 9 analysts, with a consensus rating of Hold. 11% of analysts recommend a Strong Buy, 0% recommend Buy, 67% suggest Holding, 22% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of RxSight and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About RxSight (RXST) Forecast

Analysts have given RxSight (RXST) a Hold based on their latest research and market trends.

According to 9 analysts, RxSight (RXST) has a Hold consensus rating as of Jan 10, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.44, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.44, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

RxSight (RXST)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.